Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Single-Use Systems Drive Down Costs
Flexibility and Cost Effectiveness Increasingly Essential in Modern-Day Production Facilities
- The world’s population is getting older and is requiring more effective, often biological-based treatments for endemic diseases such as diabetes and rheumatoid arthritis. “In emerging markets, governments are looking to vaccinate or treat diseases in larger numbers of their population. Many of the big pharmas don’t have blockbusters in ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.